2-Pyridin-2-yl-6-thiazol-2-yl-pyrimidin-4-ylamine | 912940-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Pyridin-2-yl-6-thiazol-2-yl-pyrimidin-4-ylamine
• 英文别名: 2-pyridin-2-yl-6-(1,3-thiazol-2-yl)pyrimidin-4-amine
• CAS: 912940-87-5
• 化学式: C₁₂H₉N₅S
• 分子量: 255.303
• InChiKey: RDHZOMGQISKGQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-Pyridin-2-yl-6-thiazol-2-yl-pyrimidin-4-ylamine 、 氯乙酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 2-chloro-N-(2-pyridin-2-yl-6-thiazol-2-yl-pyrimidin-4-yl)-acetamide
  参考文献：
  名称：

  Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

  摘要：

  A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency ( K-i = 0.4 nM), selectivity ( A(1)/A(2A) > 100), and efficacy ( MED 10 mg/ kg po) in the rat haloperidol- induced catalepsy model for Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.032
• 作为产物：
  描述：

  2-(6-chloro-2-(pyridin-2-yl)pyrimidin-4-yl)thiazole 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以53%的产率得到2-Pyridin-2-yl-6-thiazol-2-yl-pyrimidin-4-ylamine
  参考文献：
  名称：

  Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

  摘要：

  A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency ( K-i = 0.4 nM), selectivity ( A(1)/A(2A) > 100), and efficacy ( MED 10 mg/ kg po) in the rat haloperidol- induced catalepsy model for Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.032

文献信息

• Substituted Pyrimidines as Adenosine Receptor Antagonists
  申请人：Slee Deborah

  公开号：US20080275064A1

  公开（公告）日：2008-11-06

  Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.

  式(I)的化合物，包括药学上可接受的盐、酯、溶剂合物和立体异构体，其中R1、R2和R3的定义如本文所述。含有式(I)化合物的制药组合物，以及与其使用作为腺苷受体拮抗剂相关的方法，特别是A2A腺苷受体亚型的拮抗剂。
• 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability
  作者：Manisha Moorjani、Xiaohu Zhang、Yongsheng Chen、Emily Lin、Jaimie K. Rueter、Raymond S. Gross、Marion C. Lanier、John E. Tellew、John P. Williams、Sandra M. Lechner、Siobhan Malany、Mark Santos、Paddi Ekhlassi、Julio C. Castro-Palomino、Marı´a I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、John Saunders、Deborah H. Slee

  DOI：10.1016/j.bmcl.2008.01.036

  日期：2008.2

  In this report, the design and synthesis of a series of pyrimidine based adenosine A(2A) antagonists are described. The strategy and outcome of expanding SAR exploration to attenuate hERG and improve selectivity over A(1) are discussed. Compound 33 exhibited excellent potency, selectivity over A1, and reduced hERG liability. (c) 2008 Elsevier Ltd. All rights reserved.
• 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Almirall, S.A.

  公开号：EP1888565B1

  公开（公告）日：2011-03-23
• [EN] SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] PYRIMIDINES SUBSTITUEES UTILISEES COMME ANTAGONISTES DU RECEPTEUR D'ADENOSINE
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2006110884A2

  公开（公告）日：2006-10-19

  (EN) Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, Rl, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.(FR) Cette invention concerne des composés représentés par la formule (I), y compris des sels, esters, solvates, stéréo-isomères et promédicaments de ceux-ci, R1, R2 and R3 étant définis dans la demande. Des compositions pharmaceutiques contenant un composé de structure (I) ainsi que des procédés relatifs à l'utilisation de ces compositions sont également décrits.